Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan

OBJECTIVE: We explore factors that may have contributed to differences in treatment‐emergent adverse events in the phase 2 and phase 3 lasmiditan clinical trials. BACKGROUND: Phase 2 and phase 3 trials showed that the centrally penetrant 5‐HT(1F) agonist, lasmiditan, was effective; higher frequency...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudrow, David, Krege, John H., Hundemer, Hans P., Berg, Paul H., Khanna, Rashna, Ossipov, Michael H., Pozo‐Rosich, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064990/
https://www.ncbi.nlm.nih.gov/pubmed/31943195
http://dx.doi.org/10.1111/head.13731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064990/
https://www.ncbi.nlm.nih.gov/pubmed/31943195
http://dx.doi.org/10.1111/head.13731

Ejemplares similares